Updated:
Haemonetics
Haemonetics was incorporated in 1971 around the Latham Bowl, the first disposable centrifuge bowl for automated blood processing, and has spent five...
Haemonetics
Haemonetics was incorporated in 1971 around the Latham Bowl, the first disposable centrifuge bowl for automated blood processing, and has spent five decades expanding into plasma collection, hospital hemostasis, and blood-center software. The firm operates from a headquarters in Boston, Massachusetts, and runs its own manufacturing and R&D, rather than licensing third-party intellectual property. The company allocates capital primarily to tuck-in and adjacent-category acquisitions that extend its hospital, plasma, and blood-center franchises. Its three named business lines cover hospital technologies — including the TEG 6s hemostasis analyzer, the VASCADE vascular closure portfolio, and the Cell Saver Elite+ autotransfusion system — plasma collection systems such as the NexSys PCS with Persona technology and NexLynk DMS donor-management software, and blood-center products anchored by the ACP 215 cell-washing system and SafeTrace Tx transfusion-management platform. Geographic revenue spans the United States, Europe, and Japan (per the firm, 2023–2026). Recent confirmed deals include the 2023 acquisition of OpSens and its SavvyWire and OptoWire pressure guidewires, and the 2024 purchase of Attune Medical, which added the ensoETM proactive esophageal cooling device (per the firm, 2023–2024). The company added a manufacturing center of excellence in Clinton, Pennsylvania in 2022 and moved into its current Boston headquarters in 2019. In May 2026, Haemonetics announced it would release fourth-quarter fiscal 2026 financial results and present at the Bank of America 2026 Healthcare Conference (per firm press releases, May 2026). While Haemonetics does not operate a separate philanthropic foundation, it publishes a corporate responsibility framework that emphasizes environmental compliance and workplace safety. Haemonetics is structurally distinct because it builds and operates the physical manufacturing assets behind its consumables and devices, unlike capital-light intellectual-property licensors. Its capital-allocation model functions as an internal corporate acquirer that integrates targets directly into an existing regulated manufacturing and distribution network, which means incremental deals immediately benefit from the firm’s own FDA-cleared quality systems and hospital contracting relationships.
General information
Firm type
Asset Manager
Year founded
1971
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Frequently asked questions
How does Haemonetics allocate capital?
Haemonetics primarily deploys capital through direct acquisitions of medical-device and software companies that complement its existing hospital, plasma, and blood-center franchises. Notable transactions include the 2023 acquisition of OpSens for its SavvyWire and OptoWire pressure guidewires, and the 2024 acquisition of Attune Medical for its ensoETM esophageal cooling device (per the firm, 2023–2024). Rather than operating as a fund, it integrates acquired products into its own FDA-cleared manufacturing and distribution network.
What are Haemonetics' main business lines?
The firm organizes around three segments: hospital technologies (TEG 6s hemostasis analyzers, VASCADE vascular closure devices, and the Cell Saver Elite+ autotransfusion system), plasma collection (NexSys PCS with Persona technology and NexLynk DMS donor-management software), and blood-center products (the ACP 215 cell-washing system and SafeTrace Tx transfusion-management software). These lines are supported by proprietary software platforms designed to improve operational efficiency in each setting.
Where does Haemonetics manufacture its products?
Haemonetics operates a manufacturing center of excellence in Clinton, Pennsylvania, which opened in 2022, alongside other production and R&D facilities. The firm designs, engineers, and assembles its own centrifuges, software-controlled collection devices, and single-use consumable sets, giving it direct control over the supply chain that many smaller device companies outsource.
Is Haemonetics a single-family office or an asset manager?
Haemonetics is a publicly traded operating company (NYSE: HAE) that functions as an internal corporate acquirer rather than a family office. It uses its balance sheet to buy medical-device and software businesses and integrates them directly into its regulated manufacturing and distribution operations. There is no disclosed family-office vehicle or separate investment partnership.
What is Haemonetics' known posture on co-investments alongside external partners?
The firm has not disclosed any co-investment vehicles or club-deal structures. Its acquisition strategy relies on wholly owned transactions, such as the OpSens and Attune Medical purchases, with no public reporting of minority stakes or side-by-side investments alongside financial sponsors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: